Laborie picks up Andromeda Medizinische Systems and its urodynamics devices

Since Laborie's investors sold it to Patricia Industries last summer, the Toronto-based devicemaker has completed more than 14 acquisitions.

Pelvic health player Laborie is boosting its urodynamics stable with an acquisition of Andromeda Medizinische Systems. Financial details were not disclosed.

Toronto-based Laborie supplies devices and consumables in the pelvic health and gastrointestinal markets. Its products are used to diagnose and treat a range of conditions, including urinary incontinence, swallowing disorders and gastroesophageal reflux disease.

Laborie manufactures most of its products in Canada. The acquisition of Potzham, Germany-based Andromeda will increase the company’s global reach and add a range of devices to its urodynamics offerings. These products include flow meters to diagnose and treat patients with urinary incontinence as well as diagnostic catheters.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Last August, Audax Private Equity and other investors sold Laborie to Patricia Industries. At that point, Laborie had made 14 acquisitions since Audax’s initial investment in 2012.

"This is another important acquisition for LABORIE as we build out a strong global platform," stated Laborie CEO Brian Ellacott, in a statement. "Andromeda has built a very loyal customer base in Europe and we look forward to working with the Andromeda team to provide more products and services to their customers."

Suggested Articles

Thermo Fisher Scientific has begun early talks to take over Dutch diagnostics maker Qiagen, according to reports.

Atomwise and Velocity Pharmaceutical Development co-founded a company to carry AI-derived drugs through preclinical testing and into takeout deals.

Sera Prognostics has raised $36 million in funding to help commercialize its blood test for assessing the risk of premature births.